Purpose: To describe clinical results of Ahmed glaucoma valve implantation in Mexican patients with neovascular glaucoma (NVG).
INTRODUCTION
Glaucoma surgery can be classified as either filtering (increa sing outflow) or cyclodestructive (reducing inflow) procedures. Filtration has traditionally been the procedure of first resort because of its efficacy and relative predictability.
1 Initially, tube shunts were used in eyes with limited visual potential, often in cases where trabeculectomy had already failed, or where trabecu lectomy was considered unlikely to succeed. As tube shunts have proven their effectiveness and have shown reduced complication rates compared to traditional filtering surgery, they are being considered more and more as an initial surgical intervention for many types of glaucoma. 2, 3 Neovascular glaucoma (NVG) frequently fails to respond to medical therapy, and trabeculectomy has a high likelihood for failure. Several studies have reported adequate success rates for drainage implants. 46 In a study with the Ahmed glaucoma valve (AGV), the success rate was 68% after an average followup of 13 months.
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Results of drainage implants in NVG were first reported by Molteno, 8 but several, mainly retrospective, studies have described the results after Krupin implant, Baerveldt implant and also Ahmed glaucoma valve. 3, 4, 9, 10 This study aims to evaluate the results of Ahmed glaucoma valve surgery in neovascular glaucoma in a Mexican population.
MATeRIALS AND MeTHODS
The singlecenter, retrospective case series was approved by the Institutional Review Board. The consecutive records of patients with NVG due to proliferative diabetic retinopathy who underwent implantation of Ahmed glaucoma valve S2 (New World Medical Inc., Rancho Cucamonga, California) in 2012 were reviewed. All the surgeries were performed by the same surgeon Gabriel LazcanoGomez (GLG). Neovascular glaucoma was defined as neovascularization of the iris and/or anterior chamber angle (NVI/A), with elevated intraocular pressure (IOP)(> 22 mm Hg) that was not responsive to medical therapy with glaucoma medication and previous laser therapy (retina photocoagulation). A minimum followup of 1 year after surgery was needed for patients to be included in the study. We excluded patients younger than 18 years old, with previous cyclodestructive procedure or previous glaucoma drainage implant. Patients with no light perception were also excluded.
Surgical Technique
All patients had subtenon's anesthesia (2 cc lidocaine 2%) and a fornixbased incision was made through the JOCGP conjunctiva and Tenon's capsule with radial relaxing incisions on both sides of the conjunctival flap. Ahmed glaucoma valve implants S2 were placed into the pocket between the rectus muscles in the superotemporal quadrant. The valves were fixated at 8 to 9 mm posterior to the limbus with a 7 to 0 silk suture on a spatulated needle though the openings on the anterior edge of the plate. A long needle tract was created with a 23 gauge needle, starting 4 mm behind to the limbus, and viscoelastic was injected into the anterior chamber. The drainage tube was cut bevel up to allow the tube tip to extend approximately 3 mm into the anterior chamber. Conjunctival incisions were closed using the same 7 to 0 silk suture, that were removed 8 to 15 days after the surgery. Topical steroid and antibiotics were started on postoperative day 1 and tapered over the next 8 weeks.
Success was defined as an IOP of > 6 mm Hg and < 21 mm Hg, with or without additional glaucoma medi cations, without further glaucoma procedures and without loss of light perception. Hypotony was defined as IOP of 5 mm Hg or less on two consecutive visits. A hyper tensive phase was defined as IOP > 21 mm Hg during the first 3 months after surgery.
Preoperative baseline information for each patient included: age, sex, best corrected visual acuity (BCVA), IOP, and number of glaucoma medications. After surgery, IOP, number of glaucoma medications, complications and extra surgical procedures on days 1, 7, 30, 60, and months 3, 6 and 12 were registered; BCVA on month 12 was also obtained.
The patients studied were divided into two groups: surgical success group, and surgical failure group, according to the definition previously stated, and both groups were compared to find differences between them.
Data were collected using Microsoft Office Excel 2007 and statistical analysis was done with R (The R Foundation for Statistical Computing, Wirtschaftsuniversität Wien, Vienna, Austria).
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To compare the 2 groups, MannWilcox U test was used for continuous variables and Fisher exact test was used for categorical variables. ShapiroWilk, Kolmogorov Smirnov y QQplot tests were applied to evaluate if IOP values had a normal distribution. Wilcoxon signed rank test was used to compare presurgery IOP with IOP values of the postoperative days; pvalue less than 0.05 was considered statistically significant.
ReSULTS
A total of 60 patients (60 eyes) were included in the study; 39 were females (65%). Mean age was 74.85 ± 9.09 years (5493 years). The etiology of the NVG was proliferative diabetic retinopathy in all patients. After 1 year of followup, 36 cases (60%) were considered successful and 24 cases (40%) failures. Of the 24 cases considered as failure, 17 eyes (71%) required additional glaucoma surgery and 6 eyes (25%) lost light perception, 7 eyes had hypotension (29%) and 22 eyes had hypertension (91%) in at least one visit. Demographic and baseline characteristics (preoperative data) are shown in Table 1 .
Mean preoperative IOP was 27.06 ± 7.25 mm Hg (1739) for the success group, and 29.04 ± 8.76 mm Hg (1746) for the failure group showing no significant difference between them (p = 0.4455; by MannWhitney test). Mean postoperative IOP was 16.58 ± 2.63 mm Hg (11 21) for the success group, and 22.54 ± 6.53 mm Hg (1437) for the failure group. Both groups had a statistically significant IOP decrease > 15 mm Hg in the first postoperative day (p = 0.0033 and p = 0.0209, respectively; by Wilcoxon signed rank test). All postoperative IOP values were statistically significantly lower when compared to preoperative IOP in both the success group and the failure group (p < 0.0001, p < 0.04, respectively; Wilcoxon signed rank test). Up to the first 2 months followup visits, there was no statistically IOP difference between the success group and the failure group with MannWhitney test; however, from the 3rd month until 1st year followup visit, there was a statistically significant IOP difference between the two groups (p < 0.05) ( Table 2 , Fig. 1 ).
We found no significant difference in success rate between patients who had preoperative IOP > 21 mm Hg and preoperative IOP < 21 mm Hg (odds ratio = 1.45, CI = 0.376.34, p = 0.76; by Fisher's exact test). Nor did we find a significant difference in the success rate in patients who had hypotension on the first day after the surgery (odds ratio = 0.76, CI = 0.192.76, p = 0.77; by Fisher's exact test).
However, we found a significant difference in success rate between patients who had a hypertensive phase at any time during the first year after the surgery vs patients with no hypertensive phase (odds ratio = 5.15, CI = 1.49 20.15, p = 0.004; by Fisher's exact test). All patients who had a hypertensive phase received up to 4 types of topical glaucoma drugs (betablockers, alpha2 agonists, carbonic anhydrase inhibitors and/or prostaglandin analog) as an initial attempt to control the high IOP, and 17 patients in the failure group (71%) required an additional glaucoma surgery (bleb fibrosis removal).
The mean number of preoperative glaucoma medi cations was 3.64 ± 0.54 in the success group and 3.58 ± 0.65 in the failure group showing no significant difference (p = 0.7321; by ttest). The success group showed a statistically significant decrease in the number of glaucoma medica tions 12 months after surgery (p < 0.0001; by ttest) but this was not the case in the failure group (p = 0.3724; by ttest). The mean number of medications was statistically significantly lower in the success group compared to the failure group 12 months after surgery (2.02 ± 0.84 vs 3.42 ± 2.39, respectively, p = 0.0055; by ttest 'lower').
Mean preoperative best corrected visual acuity (BCVA) was 0.48 (logmar) in the success group and 0.85 (logmar) in the failure group; this difference is statistically signi ficant (p = 0.0068; Wilcox signed rank test). At the final visit, BCVA was 0.84 ± 0.66 (logmar) in the success group and 1.51 ± 1.09 (logmar) in the failure group, which represent a 2 and 3Snellen lines drop, respectively (p = 0.03 vs p = 0.017; by ttest). In the success group, 31 patients´ vision (86%) deteriorated, 4 (11%) patients remained with unchanged vision and 1 (3%) improved it, but less than one Snellen line; in the failure group no patient improved their vision, 4 (17%) maintained it. However, this must be interpreted with caution because 5 patients (13.89%) in the success group and 5 (20.83%) in the failure group required phacoemulsification surgery alone, 6 patients (16.67%) in the success group and 3 (12.50%) in the failure group required phacoemulsification plus vitrectomy and 9 patients (25%) in the success group and 8 (33.33%) in the failure group required vitrectomy alone.
If we consider a BCVA threshold at logmar 0.70 (worse or equal to 20/100) we found a statistically significant difference in success rate between patients who had preoperative BCVA better than 0.70 and those who had worse preoperative BCVA (odds ratio 4.31, CI = 1.119.3, p = 0.03086; by Fisher's exacttest). Additional glaucoma surgery (bleb fibrosis removal)
(71%)
Lost light perception 6 (25%)
Hypotension

(29%)
Hypertension (at least once during follow-up)
(91%)
Postoperative complications included shallow anterior chamber in 8 patients (33.33%) [6 patients (25%) grade 2 and 2 patients (8.33%) grade 3] and hyphema in 4 patients (16.67%). The 2 patients (8.33%) with grade 3 shallow anterior chamber required surgical management of the condition (Table 3) .
DISCUSSION
Neovascular glaucoma is a known risk factor for trabe culectomy failure, and several studies have shown it to also be a risk factor for glaucoma drainage implant surgery failure.
12 This study was conducted to evaluate the success rate of Ahmed valve implantation in Mexican patients with NVG. Although different studies vary in the definition of failure, success rates for Ahmed valve implantation without further interventions after 1 year of followup reported in previous studies ranges from 62.5 13 to 83.8%;
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we found a success rate of 60% despite improvement of postoperative IOP. The main cause of surgical failure in other studies has been hypotony, 12 while we found that 91% of our patients failed due to hypertension and 71% required additional glaucoma surgery. We found BCVA to drop 2 and 3Snellen lines in the success and failure groups, respectively, while others have found BCVA to be maintained or improve 1Snellen line in most patients after treatment.
12, 14 We believe some failure cases can be explained due to the progression of the underlying retinopathy and or the presence of cataract. Ten percent of all our patients (6 of 60) lost light perception, despite initial improvement of IOP; in other studies the proportion of patients with NVG that progressed to no light perception after Ahmed valve implant ranges from 11 to 23.7%.
12,15
Hyphema has been reported by other authors as the most common complication in up to 35 to 36%; 16, 17 we found an occurrence of hyphema of 16.67%, but the most common complication found in our patients was shallow chamber, which was observed in 8 patients (33.33%), similar to the findings by Mahdy et al who found an incidence of 30%, while others have not reported this as a predominant complication. 18 We consider the success rate of glaucoma drainage implant surgery in patients with NVG must be improved by two strategies: first, finding specific risk factors that contribute to failure, and secondly, finding adjunc tive treatments that can improve the outcome.
In this study, we found that preoperative IOP and a hypotensive postoperative period do not seem to affect the surgical success rate. However, a hypertensive phase at any time during the first year, does seem to alter the success rate, so high IOP levels should be treated aggressively.
Our results show that preoperative BCVA also seems to predict a worse outcome with a threshold at logmar 0.70 (worse or equal to 20/100). We believe this is because patients with worse preoperative BCVA have longer time of evolution with NVG when they arrive at the hospital or/and have a worst underlying retinal disease. Thus, NVG must be detected and treated before BCVA decreases more than 20/100 to try and obtain a better result. A limitation to our study is that it did not account for cataracts in the patients.
There have been efforts toward finding a treatment strategy that can improve the visual outcome of patients with NVG. Park 18, 20 Prospective studies are needed to confirm or rule out such benefit. Teixeira et al 21 failed to demonstrate that the intra vitreal injection of triamcinolone acetonide in patients with NVG affected the success rate of Ahmed valve implantation. Other interventions need to be studied to find a treatment strategy that does improve the success rate in these patients. Limitations to our study are the relatively short followup period and the lack of a comparison group with another indication of Ahmed valve implantation, different to NVG.
Neovascular glaucoma patients require a multi disciplinary management that includes a retina specialist to control the underling retinopathy and an internal medicine specialist to control the underling systemic cause (that is diabetes mellitus).
CONCLUSION
In Mexican patients with NVG treated with Ahmed valve, a postoperative hypertensive phase and a preoperative BCVA worse or equal to 20/100 seem to be risk factors for surgical failure. Further studies are needed to find other risk factors associated with failure and other therapeutic strategies to improve success.
